Essa Pharma Inc. EPIX
Institutional shares held
20.9 Million
428K
calls
182K
puts
Total value of holdings
$4.17M
$85K
calls
$36K
puts
Market Cap
$8.81M
44,073,100
Shares Out.
Institutional ownership
47.34%
# of Institutions
39
We take great care to ensure that the data presented and summarized in this overview for ESSA Pharma Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EPIX
View all-
Bvf Inc San Francisco, CA11.7MShares$2.33 Million0.12% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT4.36MShares$872,4050.05% of portfolio
-
Morgan Stanley New York, NY1.9MShares$380,8120.0% of portfolio
-
Bank Of America Corp Charlotte, NC592KShares$118,3660.0% of portfolio
-
Lmr Partners LLP London, X0541KShares$108,1960.0% of portfolio
-
Shay Capital LLC New York, NY537KShares$107,3060.01% of portfolio
-
Two Sigma Investments, LP New York, NY336KShares$67,2320.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny215KShares$42,9600.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il144KShares$28,8890.0% of portfolio
-
Css LLC Chicago, IL103KShares$20,6970.0% of portfolio
Latest Institutional Activity in EPIX
Top Purchases
Top Sells
About EPIX
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Insider Transactions at EPIX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 09
2025
|
David Ross Parkinson President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
65,675
-100.0%
|
-
|
|
Oct 09
2025
|
Richard M Glickman Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
43,240
-100.0%
|
-
|
|
Oct 09
2025
|
Franklin M Berger Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
784,404
-100.0%
|
-
|
|
Oct 09
2025
|
David S. Wood Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
33,343
-100.0%
|
-
|
|
Oct 09
2025
|
Marella Thorell Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,881
-100.0%
|
-
|
|
Oct 09
2025
|
John Alexander Martin Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,299
-100.0%
|
-
|
|
Oct 09
2025
|
Scott Requadt Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
30,002
-100.0%
|
-
|
|
Oct 09
2025
|
Bvf Partners L P > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
11,481,685
-100.0%
|
-
|
|
Aug 05
2025
|
Bvf Partners L P > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
156
-0.0%
|
$156
$1.88 P/Share
|
|
Aug 05
2025
|
Bvf Partners L P > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
2,920,000
+22.21%
|
-
|
|
Nov 01
2024
|
Growth N V Biotech |
SELL
Open market or private sale
|
Direct |
7,879,583
-52.74%
|
$7,879,583
$1.53 P/Share
|
|
Oct 07
2024
|
Peter Virsik Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
694
-8.19%
|
$4,164
$6.03 P/Share
|
|
Sep 09
2024
|
Peter Virsik Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
694
-7.57%
|
$4,164
$6.0 P/Share
|
|
Sep 03
2024
|
Peter Virsik Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,082
-18.51%
|
$12,492
$6.03 P/Share
|
|
May 06
2024
|
Peter Virsik Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
694
-5.81%
|
$4,164
$6.95 P/Share
|
|
Apr 24
2024
|
Richard M Glickman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+7.98%
|
$15,000
$4.9 P/Share
|
|
Apr 05
2024
|
Peter Virsik Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
694
-5.49%
|
$4,858
$7.94 P/Share
|
|
Mar 05
2024
|
Peter Virsik Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
694
-5.21%
|
$5,552
$8.98 P/Share
|
|
Feb 06
2024
|
Peter Virsik Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
72,782
-84.52%
|
$727,820
$10.29 P/Share
|
|
Feb 06
2024
|
Peter Virsik Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
72,782
+45.81%
|
$218,346
$3.23 P/Share
|
Last 12 Months Summary
Buy / Acquisition
2.92M
Shares
From
1
Insiders
| Exercise of in-the-money or at-the-money derivatives securities | 2.92M shares |
|---|
Sell / Disposition
12.5M
Shares
From
9
Insiders
| Sale (or disposition) back to the issuer | 974K shares |
|---|---|
| Open market or private sale | 156 shares |
| Disposition due to a tender of shares in a change of control transaction | 11.5M shares |